Tumor-infiltrating lymphocytes, a neoantigen-targeting therapy, has been shown to be a potentially curative treatment for patients with metastatic melanoma, and has led to clinical responses in this population even after failure with checkpoint inhibitors
Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.
Matthew J. Matasar, MD, Memorial Sloan Kettering Cancer Center Bergen, discusses the rationale for combining copanlisib and rituximab in patients with indolent non-Hodgkin lymphoma.
Xiuning Le, MD, PhD, discusses next steps with poziotinib (NOV120101, HM781-36B) in patients with EGFR-positive or HER2-positive exon 20–mutant non–small cell lung cancer.
Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.
Effective early detection and optimal management are critical in preventing high-grade interstitial lung disease, a treatment-related adverse effect of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive metastatic breast cancer.
The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.
Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.
Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.
Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.
Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.
Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.
Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.
Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.
Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.
The addition of SDX-7320, a novel inhibitor of methionine aminopeptidase 2, to palbociclib was found to inhibit MCF-7 tumor growth and reduce the expression of proteins associated with resistance to palbociclib.
Samuel Ahuno discusses bringing precision medicine in cancer care to Ghana.
Matthew J. Matasar, MD, discusses the efficacy of copanlisib plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma.
A triplet combination regimen that targets PIK3CA mutations, ER, and CDK4/6 can reduce and inhibit tumor growth in preclinical models of estrogen receptor–positive breast cancer that is resistant to fulvestrant plus a CDK4/6 inhibitor or PI3K inhibitor.
Plasma-based cell-free DNA appears to be a viable strategy comparable with tissue-based testing for selecting patients with KRAS G12C–mutant non–small cell lung cancer for treatment with sotorasib.
Saima Hassan, MD, PhD, FRCSC, discusses the rationale for examining talazoparib in combination with carboplatin in patients with triple-negative breast cancer.
Vivek Subbiah, MD, discusses outcomes with selpercatinib in patients with RET fusion–positive cancer.
Significant tumor necrosis was observed in 20% of patients with resectable hepatocellular carcinoma who received neoadjuvant treatment with cemiplimab-rwlc.
The majority of independently adjudicated interstitial lung disease cases associated with fam-trastuzumab deruxtecan-nxki were low grade and occurred within the first 12 months of treatment, with lower risk of developing the effect observed in patients who were on the drug for longer than 1 year.
Atezolizumab elicited durable clinical activity irrespective of microsatellite instability status in patients with advanced solid tumors with a tumor mutational burden of more than 16 mutations per megabase.
AFM13, an innate cell engager, demonstrated an objective response rate of 100% in adult patients with CD30-positive, relapsed/refractory Hodgkin lymphoma.
A multi-omics approach to personalized therapy that incorporates information about actionable oncogenic drivers with critical biological data has demonstrated feasibility in patients metastatic breast cancer vs DNA sequencing alone.
Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer.
Patients with heavily pretreated metastatic castration-resistant prostate cancer who have germline and/or homozygous tumor DNA damage response alterations have been shown to have a higher likelihood of responding to treatment with talazoparib.
Treatment with D-0316 demonstrated encouraging clinical activity in select patients with EGFR T790M-positive non–small cell lung cancer who progressed on prior therapy.
